DiaDeep

2 out of 10 cancer patients receive inappropriate therapy due to a lack of access to tests illuminating individual risk.

DiaDeep, a Lyon-based startup, has developed Deep Learning models based on the analysis of histology slide images, providing personalized risk assessments.

Our solutions, endorsed by The United States and Canadian Academy of Pathology and the European Society For Medical Oncology, target breast, colon, and melanoma cancers.

We aim to enhance survival chances and reduce expenses associated with inappropriate therapies."